Platelet/Endothelial Biomarkers in Depressed Patients Treated With the Selective Serotonin Reuptake Inhibitor Sertraline After Acute Coronary Events

DOI Web Site 3 Citations
  • Victor L. Serebruany
    From the Sinai Center for Thrombosis Research (V.L.S., A.I.M.), Johns Hopkins University, Baltimore, Md; Columbia University (A.H.G.), New York, NY; Emory University (C.B.N., D.L.M), Atlanta, Ga; Queen’s University (L.T.v.Z.), Kingston, Ontario, Canada; West Virginia University (M.S.F.), Morgantown, WV; Duke Clinical Research Institute (K.R.R.K, R.M.C., C.M.O.), Durham, NC; and Pfizer, Inc (M.G., W.H.), New York, NY.
  • Alexander H. Glassman
    From the Sinai Center for Thrombosis Research (V.L.S., A.I.M.), Johns Hopkins University, Baltimore, Md; Columbia University (A.H.G.), New York, NY; Emory University (C.B.N., D.L.M), Atlanta, Ga; Queen’s University (L.T.v.Z.), Kingston, Ontario, Canada; West Virginia University (M.S.F.), Morgantown, WV; Duke Clinical Research Institute (K.R.R.K, R.M.C., C.M.O.), Durham, NC; and Pfizer, Inc (M.G., W.H.), New York, NY.
  • Alex I. Malinin
    From the Sinai Center for Thrombosis Research (V.L.S., A.I.M.), Johns Hopkins University, Baltimore, Md; Columbia University (A.H.G.), New York, NY; Emory University (C.B.N., D.L.M), Atlanta, Ga; Queen’s University (L.T.v.Z.), Kingston, Ontario, Canada; West Virginia University (M.S.F.), Morgantown, WV; Duke Clinical Research Institute (K.R.R.K, R.M.C., C.M.O.), Durham, NC; and Pfizer, Inc (M.G., W.H.), New York, NY.
  • Charles B. Nemeroff
    From the Sinai Center for Thrombosis Research (V.L.S., A.I.M.), Johns Hopkins University, Baltimore, Md; Columbia University (A.H.G.), New York, NY; Emory University (C.B.N., D.L.M), Atlanta, Ga; Queen’s University (L.T.v.Z.), Kingston, Ontario, Canada; West Virginia University (M.S.F.), Morgantown, WV; Duke Clinical Research Institute (K.R.R.K, R.M.C., C.M.O.), Durham, NC; and Pfizer, Inc (M.G., W.H.), New York, NY.
  • Dominique L. Musselman
    From the Sinai Center for Thrombosis Research (V.L.S., A.I.M.), Johns Hopkins University, Baltimore, Md; Columbia University (A.H.G.), New York, NY; Emory University (C.B.N., D.L.M), Atlanta, Ga; Queen’s University (L.T.v.Z.), Kingston, Ontario, Canada; West Virginia University (M.S.F.), Morgantown, WV; Duke Clinical Research Institute (K.R.R.K, R.M.C., C.M.O.), Durham, NC; and Pfizer, Inc (M.G., W.H.), New York, NY.
  • Louis T. van Zyl
    From the Sinai Center for Thrombosis Research (V.L.S., A.I.M.), Johns Hopkins University, Baltimore, Md; Columbia University (A.H.G.), New York, NY; Emory University (C.B.N., D.L.M), Atlanta, Ga; Queen’s University (L.T.v.Z.), Kingston, Ontario, Canada; West Virginia University (M.S.F.), Morgantown, WV; Duke Clinical Research Institute (K.R.R.K, R.M.C., C.M.O.), Durham, NC; and Pfizer, Inc (M.G., W.H.), New York, NY.
  • Mitchell S. Finkel
    From the Sinai Center for Thrombosis Research (V.L.S., A.I.M.), Johns Hopkins University, Baltimore, Md; Columbia University (A.H.G.), New York, NY; Emory University (C.B.N., D.L.M), Atlanta, Ga; Queen’s University (L.T.v.Z.), Kingston, Ontario, Canada; West Virginia University (M.S.F.), Morgantown, WV; Duke Clinical Research Institute (K.R.R.K, R.M.C., C.M.O.), Durham, NC; and Pfizer, Inc (M.G., W.H.), New York, NY.
  • K. Ranga R. Krishnan
    From the Sinai Center for Thrombosis Research (V.L.S., A.I.M.), Johns Hopkins University, Baltimore, Md; Columbia University (A.H.G.), New York, NY; Emory University (C.B.N., D.L.M), Atlanta, Ga; Queen’s University (L.T.v.Z.), Kingston, Ontario, Canada; West Virginia University (M.S.F.), Morgantown, WV; Duke Clinical Research Institute (K.R.R.K, R.M.C., C.M.O.), Durham, NC; and Pfizer, Inc (M.G., W.H.), New York, NY.
  • Michael Gaffney
    From the Sinai Center for Thrombosis Research (V.L.S., A.I.M.), Johns Hopkins University, Baltimore, Md; Columbia University (A.H.G.), New York, NY; Emory University (C.B.N., D.L.M), Atlanta, Ga; Queen’s University (L.T.v.Z.), Kingston, Ontario, Canada; West Virginia University (M.S.F.), Morgantown, WV; Duke Clinical Research Institute (K.R.R.K, R.M.C., C.M.O.), Durham, NC; and Pfizer, Inc (M.G., W.H.), New York, NY.
  • Wilma Harrison
    From the Sinai Center for Thrombosis Research (V.L.S., A.I.M.), Johns Hopkins University, Baltimore, Md; Columbia University (A.H.G.), New York, NY; Emory University (C.B.N., D.L.M), Atlanta, Ga; Queen’s University (L.T.v.Z.), Kingston, Ontario, Canada; West Virginia University (M.S.F.), Morgantown, WV; Duke Clinical Research Institute (K.R.R.K, R.M.C., C.M.O.), Durham, NC; and Pfizer, Inc (M.G., W.H.), New York, NY.
  • Robert M. Califf
    From the Sinai Center for Thrombosis Research (V.L.S., A.I.M.), Johns Hopkins University, Baltimore, Md; Columbia University (A.H.G.), New York, NY; Emory University (C.B.N., D.L.M), Atlanta, Ga; Queen’s University (L.T.v.Z.), Kingston, Ontario, Canada; West Virginia University (M.S.F.), Morgantown, WV; Duke Clinical Research Institute (K.R.R.K, R.M.C., C.M.O.), Durham, NC; and Pfizer, Inc (M.G., W.H.), New York, NY.
  • Christopher M. O’Connor
    From the Sinai Center for Thrombosis Research (V.L.S., A.I.M.), Johns Hopkins University, Baltimore, Md; Columbia University (A.H.G.), New York, NY; Emory University (C.B.N., D.L.M), Atlanta, Ga; Queen’s University (L.T.v.Z.), Kingston, Ontario, Canada; West Virginia University (M.S.F.), Morgantown, WV; Duke Clinical Research Institute (K.R.R.K, R.M.C., C.M.O.), Durham, NC; and Pfizer, Inc (M.G., W.H.), New York, NY.

Bibliographic Information

Other Title
  • The Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy

Search this article

Description

<jats:p> <jats:bold> <jats:italic>Background—</jats:italic> </jats:bold> Depression after acute coronary syndromes (ACSs) has been identified as an independent risk factor for subsequent cardiac death. Enhanced platelet activation has been hypothesized to represent 1 of the mechanisms underlying this association. Selective serotonin reuptake inhibitors (SSRIs) are known to inhibit platelet activity. Whether treatment of depressed post-ACS patients with SSRIs alters platelet function was not known. Accordingly, we serially assessed the release of established platelet/endothelial biomarkers in patients treated with sertraline vs placebo in the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART). </jats:p> <jats:p> <jats:bold> <jats:italic>Methods and Results—</jats:italic> </jats:bold> Plasma samples (baseline, week 6, and week 16) were collected from patients randomized to sertraline (n=28) or placebo (n=36). Anticoagulants, aspirin, and ADP-receptor inhibitors were permitted in this study. Platelet factor 4, β-thromboglobulin (βTG), platelet/endothelial cell adhesion molecule-1, P-selectin, thromboxane B <jats:sub>2</jats:sub> , 6-ketoprostaglandin F <jats:sub>1a</jats:sub> , vascular cell adhesion molecule-1, and E-selectin were measured by ELISA. Treatment with sertraline was associated with substantially less release of platelet/endothelial biomarkers than was treatment with placebo. These differences attained statistical significance for βTG ( <jats:italic>P</jats:italic> =0.03) at weeks 6 and 16 and for P-selectin ( <jats:italic>P</jats:italic> =0.04) at week 16. Repeated-measures ANOVA revealed a significant advantage for sertraline vs placebo for diminishing E-selectin and βTG concentrations across the entire treatment period. </jats:p> <jats:p> <jats:bold> <jats:italic>Conclusions—</jats:italic> </jats:bold> Treatment with sertraline in depressed post-ACS patients is associated with reductions in platelet/endothelial activation despite coadministration of widespread antiplatelet regimens including aspirin and clopidogrel. The antiplatelet and endothelium-protective properties of SSRIs might represent an attractive additional advantage in patients with depression and comorbid coronary artery and/or cerebrovascular disease. </jats:p>

Journal

  • Circulation

    Circulation 108 (8), 939-944, 2003-08-26

    Ovid Technologies (Wolters Kluwer Health)

Citations (3)*help

See more

Details 詳細情報について

Report a problem

Back to top